OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis
Status:
Completed
Trial end date:
2021-04-08
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to assess the safety and efficacy of MS1819 in
enteric capsules vs porcine pancreatic enzyme replacement therapy (PERT) in patients with
exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF). The exploratory
objective of the extension phase (EP) is to find a dose of MS1819 in immediate release
capsules that is safe and results in CFA values in a therapeutic range.